1 domain / 1 area / 1 specialization
ARTIS Ventures
Also known as: ARTIS
Data updated
ARTIS Ventures is a San Francisco venture capital firm focused on frontier technologies at the intersection of life science, health, and advanced computing. Its current public language emphasizes resilience, TechBio, and backing companies that reshape human health and related systems.
ARTIS is a strong psychedelic-adjacent investor record because it has direct exposure to Delix Therapeutics and publicly hosts Delix within its portfolio. It should be described as a techbio and healthcare VC with a source-backed neuroplastogen investment, not as a dedicated psychedelic investor.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed and Series A/B. Public focus areas include Drug Development, Digital Therapeutics & Platforms, and Clinical Infrastructure.
Public Portfolio Examples
- Delix TherapeuticsSeries A - $70 million - Sep 27, 2021
Delix Therapeutics is the anchor portfolio reference for ARTIS in this dataset. The investment record is high-signal for non-hallucinogenic neuroplastogen development and can also help identify future co-investors in psychedelic-adjacent neuropsychiatry.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Portfolio Stakeholders
Recorded Investments
Sep 27, 2021
Series A - $70 million
Core psychedelic-adjacent record in non-hallucinogenic neuroplastogens; also matched by ARTIS portfolio materials.
Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain DisordersQuick Facts
- Founded
- 2001
- HQ
- San Francisco, California, United States
- Website
- Visit